Osteoporosis in postmenopausal woman at high risk for fracture

Osteoporosis in a postmenopausal woman at high risk for fracture refers to a systemic skeletal disorder characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of bone tissue following natural or surgical menopause

Osteoporosis in a postmenopausal woman at high risk for fracture refers to a systemic skeletal disorder characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of bone tissue following natural or surgical menopause

Pathophysiologically, the cessation of ovarian function leads to estrogen deficiency, accelerating osteoclast-mediated bone resorption beyond bone formation and resulting in progressive skeletal fragility

Pathophysiologically, the cessation of ovarian function leads to estrogen deficiency, accelerating osteoclast-mediated bone resorption beyond bone formation and resulting in progressive skeletal fragility

The high-risk designation identifies patients with an elevated probability of imminent or future fragility fractures, clinically defined by criteria such as a history of osteoporotic or fragility fractures, very low bone mineral density (T-score of –2.5 or lower), multiple clinical fracture risk factors, a high FRAX score, or previous failure or intolerance to other osteoporosis therapies

The high-risk designation identifies patients with an elevated probability of imminent or future fragility fractures, clinically defined by criteria such as a history of osteoporotic or fragility fractures, very low bone mineral density (T-score of –2.5 or lower), multiple clinical fracture risk factors, a high FRAX score, or previous failure or intolerance to other osteoporosis therapies

The high-risk designation identifies patients with an elevated probability of imminent or future fragility fractures, clinically defined by criteria such as a history of osteoporotic or fragility fractures, very low bone mineral density (T-score of –2.5 or lower), multiple clinical fracture risk factors, a high FRAX score, or previous failure or intolerance to other osteoporosis therapies